Attention-Deficit/Hyperactivity Disorder (ADHD)
Conditions
Keywords
Attention-Deficit/Hyperactivity Disorder (ADHD, Repetitive transcranial magnetic stimulation (rTMS)
Brief summary
Attention-Deficit/Hyperactivity Disorder (ADHD) is characterized by poor attention, impulsivity, hyperactivity and emotional-motivational dysregulation. Here, we will test if theta burst repetitive transcranial magnetic stimulation (rTMS) can reduce the symptoms of ADHD.
Detailed description
Background & Rationale Attention-Deficit/Hyperactivity Disorder (ADHD) is characterized by poor attention, impulsivity, hyperactivity and emotional-motivational dysregulation. It has an estimated prevalence of 5% in children. Usually, ADHD in children is treated with stimulant medications, such as methylphenidate. However, these pharmacotherapy treatments have numerous unwanted side effects, including sleep disturbances, appetite changes, and emotional lability, and do not prove to be effective in every case. A promising and alternative option for reducing ADHD symptoms is non-invasive brain stimulation. Repetitive transcranial magnetic stimulation (rTMS) is a form of non-invasive brain stimulation which involves the application of a magnetic field to the skull to change the behaviour and function of underlying brain areas. In turn, rTMS leads to positive long-term changes in neurochemical activity, and while studies are limited, some have shown that rTMS can reduce ADHD symptoms in adolescents with ADHD. Methods Design: Open label TMS trial Primary Outcome: To examine the effect of active rTMS to the right prefrontal cortex on attention as measured by the TEACh-2 Outline: 1. Baseline Assessment (MRI Scan, assessment scales, neuropsychological testing) 2. rTMS intervention: 5 / week for 4 weeks. 3. Post-intervention Assessment (MRI Scan, assessment scales, neuropsychological testing).
Interventions
DEVICErTMS
Repetitive transcranial magnetic stimulation (rTMS)
Sponsors
University of Calgary
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Open label
Eligibility
Sex/Gender
ALL
Age
9 Years to 15 Years
Healthy volunteers
No
Inclusion criteria
1. Diagnosis of ADHD 2. 9-15 years old 3. IQ greater than 80 4. English fluency (to enable consent/assent) 5. If on medication, must have been on the same type and dosage for at least 3 months.
Exclusion criteria
1. Diagnosis of mania, psychosis, or bipolar disorder 2. Impediments to TMS or MRI (i.e. metal implants in body) 3. Prior electroconvulsive therapy or vagus nerve stimulation 4. Diagnosis of Autism Spectrum Disorder.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| TEACH-2 | Baseline to week 5 | Test of everyday attention in children - 2. Direct assessment of attention abilities in children. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| SNAP-18 | 5 weeks and 52 weeks. | Parent reporting of ADHD symptom severity |
| PedsQL | Baseline to week 5 | Self reporting of quality of life |
Countries
Canada
Outcome results
None listed